Literature DB >> 20865325

Screening of substrate peptide sequences for tissue-type transglutaminase (TGase 2) using T7 phage cDNA library.

Yoshiaki Sugimura1, Hiroyuki Yamashita, Kiyotaka Hitomi.   

Abstract

Transglutaminase (TGase) is a family of enzymes that catalyzes cross-linking reaction between glutamine- and lysine residue of substrate proteins in several mammalian biological events. Substrate proteins for TGase and their physiological relevance have been still in research, continuously expanding. In this study, we have established a novel screening system that enables identification of cDNA sequence encoding favorable primary structure as a substrate for tissue-type transglutaminase (TGase 2), a multifunctional and ubiquitously expressing isozyme. By the screening, we identified several T7 phage clones that displayed substrate peptides for TGase 2 as a translated product from human brain cDNA library. Among the selected clones, the C-terminal region of IKAP, IkappaB kinase complex associated protein, appeared as a highly reactive substrate sequence for TGase 2. This system will open possibility of rapid identification of substrate sequences for transglutaminases at a genetic level.

Entities:  

Year:  2010        PMID: 20865325      PMCID: PMC3080479          DOI: 10.1007/s10616-010-9308-7

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  26 in total

1.  Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library: identification of peptide substrates for TGASE 2 and Factor XIIIA.

Authors:  Yoshiaki Sugimura; Masayo Hosono; Fumitaka Wada; Tohru Yoshimura; Masatoshi Maki; Kiyotaka Hitomi
Journal:  J Biol Chem       Date:  2006-04-24       Impact factor: 5.157

Review 2.  Transglutaminases: crosslinking enzymes with pleiotropic functions.

Authors:  Laszlo Lorand; Robert M Graham
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

Review 3.  Transglutaminase function in epidermis.

Authors:  Richard L Eckert; Michael T Sturniolo; Ann-Marie Broome; Monica Ruse; Ellen A Rorke
Journal:  J Invest Dermatol       Date:  2005-03       Impact factor: 8.551

Review 4.  Physiopathology and regulation of factor XIII.

Authors:  A Ichinose
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

Review 5.  Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance.

Authors:  Carla Esposito; Ivana Caputo
Journal:  FEBS J       Date:  2005-02       Impact factor: 5.542

6.  Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a human intestinal epithelial cell line. Implications for celiac disease.

Authors:  Stefania Orrù; Ivana Caputo; Alfonsina D'Amato; Margherita Ruoppolo; Carla Esposito
Journal:  J Biol Chem       Date:  2003-06-10       Impact factor: 5.157

7.  Familial dysautonomia is caused by mutations of the IKAP gene.

Authors:  S L Anderson; R Coli; I W Daly; E A Kichula; M J Rork; S A Volpi; J Ekstein; B Y Rubin
Journal:  Am J Hum Genet       Date:  2001-01-22       Impact factor: 11.025

Review 8.  Coeliac disease: dissecting a complex inflammatory disorder.

Authors:  Ludvig M Sollid
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

9.  Identification of amine acceptor protein substrates of transglutaminase in liver extracts: use of 5-(biotinamido) pentylamine as a probe.

Authors:  K Ikura; K Kita; I Fujita; H Hashimoto; N Kawabata
Journal:  Arch Biochem Biophys       Date:  1998-08-15       Impact factor: 4.013

10.  IKAP is a scaffold protein of the IkappaB kinase complex.

Authors:  L Cohen; W J Henzel; P A Baeuerle
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

View more
  1 in total

Review 1.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.